Specialty medicines • Bangladesh

Renaxen 5 MG (Axitinib)

Product Name : Renaxen
Generic Name : Axitinib
Formulation : Film-Coated Tablet
Available Pack Size : 60 Tablets per pot
Available Strengths : 5 mg
Manufacturer : Everest Pharmaceuticals Ltd.
Country Of Origin : Bangladesh

Confirm your order

Speak with our team about your prescribed strength, pack size, price and delivery.
Use medicines only as prescribed by your clinician.

Description

Renaxen 5 MG (Axitinib) is an oral, selective vascular endothelial growth factor receptor (VEGFR) inhibitor film-coated tablet available in a 5 mg strength, supplied in a pack of 60 tablets per pot, manufactured by Everest Pharmaceuticals Ltd. of Bangladesh. The active ingredient, axitinib, is a potent and selective second-generation inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 the three vascular endothelial growth factor receptors that drive pathological tumour angiogenesis across multiple solid tumour types with reported IC₅₀ values of 0.1 nM (VEGFR-1), 0.2 nM (VEGFR-2), and 0.1–0.3 nM (VEGFR-3), confirming sub-nanomolar potency that mechanistically distinguishes axitinib from first-generation multi-kinase inhibitors such as sorafenib and sunitinib.

 

The reference-label starting dose of axitinib is 5 mg twice daily (BID), achieved with 1 × Renaxen 5 MG tablet in the morning and 1 × Renaxen 5 MG tablet in the evening, totalling 2 tablets (10 mg total) per day, with dose escalation to 7 mg BID and then 10 mg BID permitted in patients who tolerate the starting dose without adverse reactions exceeding Grade 2. In the pivotal Phase III AXIS trial, axitinib 5 mg BID significantly extended median progression-free survival (PFS) to 6.7 months versus 4.7 months with sorafenib (HR 0.665; 95% CI 0.544–0.812; P<0.0001) in patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy, establishing axitinib as a standard second-line treatment for advanced RCC.

 

In the Phase III KEYNOTE-426 trial, the axitinib-plus-pembrolizumab combination delivered a median PFS of 15.1 months versus 11.1 months with sunitinib (HR 0.69; P<0.001) and a 47% reduction in the risk of death (HR 0.53; P<0.0001) in treatment-naïve advanced RCC patients, earning a first-line combination indication. Searching for Renaxen 5 MG Axitinib? Mediaid Pharmacy stocks this product within its comprehensive oncology medicines portfolio and ships worldwide.

Basic Product Information of Renaxen 5 MG (Axitinib)

Brand Name Renaxen 5 MG (Axitinib)
Product Name Renaxen
Generic Name Axitinib
Drug Class Selective VEGFR-1/2/3 Inhibitor; Second-Generation Tyrosine Kinase Inhibitor (TKI); Anti-Angiogenic Targeted Oncology Agent
Formulation Film-Coated Tablet
Available Strength 5 mg per tablet
Available Pack Size 60 Tablets per pot (30-day supply at the reference-label starting dose of 2 tablets/day at 5 mg BID)
Primary Indications Advanced Renal Cell Carcinoma (RCC) after failure of one prior systemic therapy (second-line monotherapy); Advanced RCC first-line in combination with pembrolizumab (KEYNOTE-426); Advanced RCC first-line in combination with avelumab in PD-L1-positive patients (JAVELIN Renal 101)
Reference-Label Starting Dose 5 mg twice daily (BID) = 1 × Renaxen 5 MG tablet in the morning + 1 × Renaxen 5 MG tablet in the evening (10 mg total per day); taken with or without food
Manufacturer / Brand Everest Pharmaceuticals Ltd., Bangladesh
Country of Origin Bangladesh
SKU everest-renaxen-5
Categories Everest Pharmaceuticals Medicines, Kidney Cancer Medicines, Oncology Medicines
Storage Conditions Store below 25°C in a dry place, protected from light and moisture. Keep out of the reach of children.
Global Supplier Mediaid Pharmacy Worldwide Shipping Available

How Renaxen 5 MG (Axitinib) Works: Selective VEGFR-1/2/3 Inhibition and Potent Anti-Angiogenic Tumour Vascular Blockade

Axitinib, the active ingredient in Renaxen 5 MG, is an orally bioavailable, selective second-generation tyrosine kinase inhibitor (TKI) belonging to the indazole chemical class. Axitinib is mechanistically defined by its highly selective and potent inhibition of all three primary vascular endothelial growth factor receptors: VEGFR-1, VEGFR-2, and VEGFR-3 the receptors responsible for initiating and sustaining pathological tumour angiogenesis, the formation of new blood vessels required for tumour growth, invasion, and metastatic dissemination. A selective VEGFR inhibitor refers to a small-molecule drug that competitively occupies the ATP-binding domains of VEGFR kinases with high selectivity, thereby preventing receptor autophosphorylation and downstream propagation of pro-angiogenic signalling cascades through the PI3K/AKT and RAS/MAPK pathways.

Axitinib achieves sub-nanomolar inhibitory activity across its target receptor panel, with reported IC₅₀ values of 0.1 nM (VEGFR-1), 0.2 nM (VEGFR-2), and 0.1–0.3 nM (VEGFR-3) potency levels approximately 50- to 450-fold greater than first-generation VEGFR inhibitors such as sorafenib and sunitinib at equivalent receptor targets confirming mechanistically superior vascular endothelial growth factor receptor blockade at therapeutically relevant plasma concentrations. Each Renaxen 5 MG film-coated tablet contains axitinib equivalent to 5 mg, with the reference-label starting dose of 5 mg BID delivered by taking 1 tablet in the morning and 1 tablet in the evening.

The oncological primacy of axitinib’s selective VEGFR-1/2/3 inhibition lies in its mechanistic precision and potency across the complete VEGF receptor axis. VEGFR-2 (KDR) is the primary mediator of VEGF-driven endothelial cell proliferation, survival, and migration; its inhibition by axitinib at IC₅₀ 0.2 nM directly suppresses the formation of new tumour blood vessels, starving the tumour of oxygen and nutrients required for growth. VEGFR-1 (Flt-1) regulates VEGF bioavailability and vascular permeability; its blockade by axitinib further constrains the VEGF signalling reserve available to stimulate new vessel formation. VEGFR-3 governs tumour lymphangiogenesis the formation of new lymphatic vessels that facilitate regional and distant metastatic spread; its inhibition by axitinib at IC₅₀ 0.1–0.3 nM addresses a metastatic dissemination axis that is frequently clinically underappreciated.

In advanced renal cell carcinoma (RCC), axitinib’s selectivity delivers a mechanistic advantage: clear cell RCC is characterised by near-universal inactivation of the VHL (von Hippel-Lindau) tumour suppressor gene, which causes constitutive overexpression of HIF-1α and consequently markedly elevated VEGF and VEGFR signalling making clear cell RCC uniquely dependent on the VEGF/VEGFR axis that axitinib selectively ablates. Oncologists managing patients with kidney cancer can review the full range of kidney cancer medicines at Mediaid Pharmacy, including Renaxen 5 MG Axitinib, for second-line and combination RCC therapy planning.

In the pivotal Phase III AXIS trial of advanced renal cell carcinoma 723 patients who had failed one prior first-line therapy (sunitinib, bevacizumab, temsirolimus, or cytokine-based regimens) axitinib 5 mg BID (achievable as 2 × Renaxen 5 MG tablets per day) extended median progression-free survival to 6.7 months versus 4.7 months with sorafenib (HR 0.665; 95% CI 0.544–0.812; P<0.0001), representing a 44% improvement in median PFS.

In the Phase III KEYNOTE-426 trial of treatment-naïve advanced RCC 861 patients the combination of axitinib 5 mg BID plus pembrolizumab 200 mg Q3W significantly improved PFS to 15.1 months versus 11.1 months with sunitinib (HR 0.69; 95% CI 0.57–0.84; P<0.001) and reduced the risk of death by 47% (HR 0.53; 95% CI 0.38–0.74; P<0.0001). In the Phase III JAVELIN Renal 101 trial in PD-L1-positive treatment-naïve advanced RCC 886 patients axitinib 5 mg BID plus avelumab 10 mg/kg Q2W delivered a median PFS of 13.8 months versus 7.2 months with sunitinib (HR 0.61; 95% CI 0.475–0.790; P<0.001) in the PD-L1-positive population. The axitinib dose for each patient and regimen is determined and adjusted by the treating oncologist; Renaxen 5 MG tablets must be prescribed and administered under the supervision of a qualified oncology specialist.

Approved Indications of Axitinib Renaxen 5 MG Reference Label

Axitinib is approved in numerous countries across three primary oncology settings in adult patients with advanced renal cell carcinoma. The 5 mg film-coated tablet formulation of Renaxen, with its 60-tablet pack size, supports the reference-label 5 mg BID starting dose and the dose escalation to 10 mg BID in patients who tolerate therapy. Prescribers must confirm the exact locally approved indications on the axitinib product label before initiating therapy, as specific label language and combination approvals vary by regulatory jurisdiction.

Advanced Renal Cell Carcinoma (RCC) Second-Line Monotherapy After Prior Systemic Therapy

Axitinib is indicated as monotherapy for adult patients with advanced renal cell carcinoma after failure of one prior systemic therapy (sunitinib, cytokine-based therapy, bevacizumab, or temsirolimus). Reference-label starting dose: 5 mg twice daily (BID) = 2 × Renaxen 5 MG tablets per day (1 in the morning, 1 in the evening). The AXIS Phase III trial confirmed median PFS of 6.7 vs 4.7 months (HR 0.665; P<0.0001) versus sorafenib. Oncologists can review the full range of kidney cancer targeted therapy medicines at Mediaid Pharmacy alongside Renaxen for comprehensive second-line RCC programme planning.

First-Line Advanced RCC In Combination with Pembrolizumab (KEYNOTE-426)

Axitinib is indicated in combination with pembrolizumab for treatment-naïve adult patients with advanced renal cell carcinoma. Reference-label axitinib dose: 5 mg twice daily (BID) = 2 × Renaxen 5 MG tablets per day, combined with pembrolizumab 200 mg every 3 weeks. KEYNOTE-426 Phase III data: median PFS 15.1 vs 11.1 months (HR 0.69; P<0.001); OS HR 0.53 (P<0.0001). The complete selection of kidney cancer combination therapy medicines at Mediaid Pharmacy supports first-line axitinib-based RCC programme planning.

First-Line Advanced RCC In Combination with Avelumab in PD-L1-Positive Patients (JAVELIN Renal 101)

Axitinib is indicated in combination with avelumab for treatment-naïve adult patients with advanced RCC who are PD-L1 positive. Reference-label axitinib dose: 5 mg twice daily (BID) = 2 × Renaxen 5 MG tablets per day, combined with avelumab 10 mg/kg Q2W. JAVELIN Renal 101 Phase III data: median PFS 13.8 vs 7.2 months (HR 0.61; P<0.001) in PD-L1-positive patients. Oncologists can review oncology combination therapy medicines at Mediaid Pharmacy for first-line immunotherapy-TKI RCC regimen planning.

Axitinib Dose Modification and Escalation Framework: How Renaxen 5 MG Tablets Cover the Reference-Label Starting Dose and Escalation

The reference label for axitinib specifies both a dose escalation pathway for well-tolerating patients and a stepwise dose reduction algorithm for toxicity management, across all approved indications. The Renaxen 5 MG film-coated tablet enables complete reference-label dose coverage at the 5 mg BID starting dose and the 10 mg BID escalated dose, using 1 tablet per dose as the fundamental unit. For the 5 mg BID starting dose, 1 Renaxen 5 MG tablet is taken twice daily; dose escalation to 10 mg BID is achieved with 2 Renaxen 5 MG tablets taken twice daily. The 60-tablet pot of Renaxen 5 MG provides a 30-day supply at the 5 mg BID starting dose (2 tablets/day). The table below maps each reference-label dose level to the precise Renaxen 5 MG tablet count required. All dose modifications and escalations must be directed and supervised by the treating oncologist; never alter the dose without an explicit clinical instruction.

Indication & Regimen Dose Level Daily Dose Renaxen 5 MG Tablet Count
Advanced RCC Second-Line Monotherapy Starting Dose 5 mg BID (10 mg/day) 1 tablet in the morning + 1 tablet in the evening = 2 tablets/day
Escalation 1 (if tolerated) 10 mg BID (20 mg/day) 2 tablets in the morning + 2 tablets in the evening = 4 tablets/day
Reduction (for toxicity) 3 mg BID or 2 mg BID (requires 1 mg tablets; per oncologist direction) Per oncologist instruction using appropriate tablet strengths
Advanced RCC First-Line + Pembrolizumab (KEYNOTE-426) Starting Dose 5 mg BID (10 mg/day) 1 tablet in the morning + 1 tablet in the evening = 2 tablets/day
Escalation 1 (if tolerated) 10 mg BID (20 mg/day) 2 tablets in the morning + 2 tablets in the evening = 4 tablets/day
Reduction (for toxicity) 3 mg BID or 2 mg BID (per oncologist direction) Per oncologist instruction using appropriate tablet strengths
Advanced RCC First-Line + Avelumab (JAVELIN Renal 101) Starting Dose 5 mg BID (10 mg/day) 1 tablet in the morning + 1 tablet in the evening = 2 tablets/day
Escalation 1 (if tolerated) 10 mg BID (20 mg/day) 2 tablets in the morning + 2 tablets in the evening = 4 tablets/day
Reduction (for toxicity) 3 mg BID or 2 mg BID (per oncologist direction) Per oncologist instruction using appropriate tablet strengths

Key Clinical Benefits of Renaxen 5 MG (Axitinib)

AXIS Phase III: Second-Line RCC PFS Superiority 6.7 Months vs 4.7 Months and 44% Improvement Over Sorafenib

The AXIS Phase III trial established axitinib 5 mg BID as a superior second-line treatment for advanced RCC compared to sorafenib, confirming a 44% improvement in median PFS (6.7 vs 4.7 months; HR 0.665; P<0.0001) across 723 patients. The 5 mg BID starting dose is achievable with 2 × Renaxen 5 MG tablets per day 1 in the morning and 1 in the evening from a convenient 60-tablet pot providing a complete 30-day supply at the reference starting dose.

KEYNOTE-426 Phase III: First-Line RCC OS Benefit 47% Reduction in Risk of Death with Axitinib + Pembrolizumab Combination

The KEYNOTE-426 Phase III trial confirmed that axitinib 5 mg BID plus pembrolizumab reduced the risk of death by 47% (HR 0.53; 95% CI 0.38–0.74; P<0.0001) and extended median PFS to 15.1 versus 11.1 months (HR 0.69; P<0.001) compared to sunitinib in treatment-naïve advanced RCC, establishing axitinib as the backbone tyrosine kinase inhibitor of one of the most clinically impactful immunotherapy-TKI combinations in first-line kidney cancer. The 5 mg BID starting dose is achievable with 2 × Renaxen 5 MG tablets daily without strength adjustment.

Sub-Nanomolar VEGFR Selectivity Mechanistically Differentiated from First-Generation Multi-Kinase Inhibitors Across All RCC Settings

Axitinib’s IC₅₀ values of 0.1–0.2 nM across VEGFR-1, VEGFR-2, and VEGFR-3 deliver 50- to 450-fold greater receptor potency than first-generation VEGFR inhibitors at equivalent targets enabling deeper, more complete VEGFR pathway suppression at therapeutically tolerable systemic exposures. This selectivity profile means Renaxen 5 MG targets the exact angiogenic dependency of VHL-deficient clear cell RCC with a mechanistic precision absent from multi-kinase inhibitors that distribute kinase-inhibitory activity across non-VEGFR targets.

Clinical Monitoring Requirements During Renaxen 5 MG (Axitinib) Treatment

Blood pressure monitoring is the primary safety requirement throughout axitinib therapy at all dose levels and across all approved indications. Hypertension occurs in approximately 40% of axitinib-treated patients a substantially higher incidence than with first-generation VEGFR inhibitors and is typically an early-onset adverse event reflecting on-target VEGFR2 inhibition in the systemic vasculature. The reference label requires blood pressure measurement before initiating axitinib and monitoring throughout treatment; anti-hypertensive therapy should be initiated or intensified promptly when hypertension develops.

Blood pressure must be well controlled before initiating axitinib dose escalation from 5 mg BID to 10 mg BID. Grade 3 hypertension (systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg, despite anti-hypertensive therapy) requires axitinib dose reduction; hypertensive crisis requires permanent discontinuation. Using Renaxen 5 MG, the treating oncologist can implement precise dose reductions using the standard 1-tablet BID unit as the starting dose reference point.

Thyroid function (TSH) monitoring is mandatory at baseline and throughout axitinib treatment, as hypothyroidism occurs in approximately 19% of axitinib-treated patients a higher incidence than with most other VEGFR TKIs attributable to axitinib’s potent VEGFR-driven inhibition of thyroid vascularity. TSH should be assessed before initiating axitinib and periodically during treatment; thyroid hormone replacement should be initiated promptly when hypothyroidism is confirmed. Hepatic function monitoring is required at baseline and throughout treatment: liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) must be assessed before initiating axitinib and periodically thereafter, with Grade 3–4 hepatotoxicity requiring dose interruption or permanent discontinuation.

Proteinuria monitoring via urine protein-to-creatinine ratio or 24-hour urine protein collection is required throughout axitinib treatment; Grade 3 proteinuria (urinary protein ≥3.5 g/24 hours) requires axitinib dose interruption, and Grade 4 proteinuria requires permanent discontinuation. Wound healing assessment: axitinib impairs wound healing; it should be held for at least 24 hours before elective surgery and for a clinically appropriate period after surgical wound healing, as directed by the treating oncologist. Cardiac monitoring: axitinib may increase the risk of arterial thromboembolic events (ATE), and patients with significant cardiovascular history require heightened monitoring throughout treatment. Oncologists managing patients on axitinib who also require supportive or combination agents can review the full selection of oncology medicines at Mediaid Pharmacy for comprehensive RCC programme support.

Drug Interactions and Important Safety Information for Renaxen 5 MG (Axitinib)

The most clinically significant pharmacokinetic drug interaction risk for axitinib involves CYP3A4/5 inhibitors and inducers. Axitinib is primarily metabolised by CYP3A4/5 (accounting for approximately 50% of axitinib clearance), with minor contributions from CYP1A2, CYP2C19, and UGT1A1. Strong CYP3A4/5 inhibitors including ketoconazole, itraconazole, clarithromycin, atazanavir, ritonavir, and other HIV protease inhibitors markedly increase axitinib systemic exposure (AUC increases of approximately 2-fold with ketoconazole), amplifying toxicity risk; co-administration should be avoided where clinically feasible.

If a strong CYP3A4/5 inhibitor cannot be avoided, the reference label recommends a 50% reduction in the axitinib dose (from 5 mg BID to approximately 2 mg BID using appropriate tablet strengths), subject to the treating oncologist’s clinical judgement. Strong CYP3A4/5 inducers including rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort (Hypericum perforatum) significantly increase axitinib metabolism and reduce systemic exposure; rifampicin co-administration reduced axitinib AUC by approximately 79% in pharmacokinetic studies, virtually eliminating therapeutic plasma concentrations. Avoidance of strong CYP3A4/5 inducers is preferred; if unavoidable, gradual dose escalation of axitinib per the reference-label algorithm may be required, subject to tolerability and oncologist supervision.

Moderate CYP3A4/5 inhibitors (fluconazole, erythromycin, verapamil, diltiazem, grapefruit, Seville oranges) increase axitinib exposure to a clinically meaningful degree; patients must be advised to avoid grapefruit and grapefruit juice during Renaxen 5 MG treatment, as this is a commonly overlooked dietary interaction. Antihypertensive agents: given the high incidence of axitinib-associated hypertension (approximately 40%), many patients will require initiation or intensification of antihypertensive therapy during treatment; blood pressure monitoring frequency must be increased when antihypertensives are added or modified.

Anticoagulants and antiplatelet agents: axitinib increases the risk of haemorrhage; patients on warfarin require more frequent INR monitoring, and concurrent antiplatelet therapy (aspirin, clopidogrel) requires individualised benefit-risk assessment by the treating oncologist. Thyroid hormone replacement: given the high incidence of axitinib-associated hypothyroidism, patients who develop hypothyroidism during treatment will require levothyroxine or equivalent; TSH levels must be re-assessed and the thyroid hormone replacement dose adjusted after initiating or modifying axitinib therapy. Patients must disclose all concomitant medications including over-the-counter supplements and herbal preparations to their treating oncologist before and during Renaxen 5 MG therapy. Teams requiring concurrent oncology agents alongside axitinib-based kidney cancer regimens at Mediaid Pharmacy can contact the team for multi-medicine sourcing support.

Side Effects and Precautions of Renaxen 5 MG (Axitinib)

Common Side Effects

Diarrhoea (approximately 55%; the most frequently reported gastrointestinal adverse event with axitinib at all dose levels; typically mild to moderate; managed with anti-diarrhoeal agents, hydration, and dose modification as clinically required)

Hypertension (approximately 40%; a characteristic on-target VEGFR2 inhibition effect reflecting effective systemic VEGFR blockade; requires pre-treatment blood pressure optimisation, regular monitoring throughout therapy, and prompt initiation or intensification of anti-hypertensive therapy)

Fatigue and asthenia (approximately 39%; often multifactorial contributed to by hypothyroidism, anaemia, disease burden, and direct drug-related effects; thyroid function assessment is required when fatigue develops during axitinib therapy)

Decreased appetite and weight loss (approximately 34% and 25% respectively; nutritional support and dietary counselling may be required during prolonged axitinib treatment)

Nausea (approximately 32%) and vomiting (approximately 24%); managed with anti-emetic support as clinically required

Dysphonia (hoarseness of voice; approximately 31%; a distinctive and frequently reported axitinib-associated adverse event attributable to laryngeal mucosal changes; does not typically require dose modification but warrants patient counselling)

Hand-foot syndrome / Palmar-plantar erythrodysaesthesia (PPES; approximately 27%; managed with preventive skin care, emollient creams, dose modification when Grade 2 or higher, and dermatological assessment)

Hypothyroidism (approximately 19%; among the highest incidence of any approved VEGFR TKI; requires baseline and periodic TSH monitoring with prompt thyroid hormone replacement therapy initiation when confirmed); proteinuria (~11%); stomatitis (~15%)

Serious Warnings and Precautions

Severe hypertension and hypertensive crisis: Grade 3 hypertension (systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg despite anti-hypertensive therapy) requires axitinib dose reduction using the reference-label dose modification algorithm. Hypertensive crisis requires permanent discontinuation. Blood pressure must be optimised before initiating axitinib and before any dose escalation, and must be monitored regularly throughout treatment.

Arterial thromboembolic events (ATE): serious ATEs including myocardial infarction, cerebrovascular accident, transient ischaemic attack, and retinal artery occlusion have been reported with axitinib in clinical trials and post-marketing experience. Patients with a history of ATE within 12 months of initiating axitinib were excluded from the AXIS trial. Axitinib must be permanently discontinued in patients who develop a Grade 3 or higher ATE during treatment.

Venous thromboembolic events (VTE): DVT and pulmonary embolism have been reported with axitinib. Patients with a history of VTE, those on anticoagulant therapy, and those with additional risk factors require heightened thromboembolism vigilance throughout axitinib treatment.

Haemorrhage: serious and potentially fatal haemorrhagic events have been reported with axitinib, including tumour-related haemorrhage, gastrointestinal haemorrhage, and pulmonary haemorrhage. Grade 3–4 haemorrhage requires axitinib dose interruption or permanent discontinuation depending on severity and clinical judgement of the treating oncologist.

Gastrointestinal perforation and fistula formation: GI perforation and fistulae have been reported with axitinib in post-marketing experience; patients with risk factors (prior abdominal surgery, irradiation, bowel obstruction) require heightened vigilance and imaging assessment if GI symptoms develop.

Reversible posterior leukoencephalopathy syndrome (RPLS): cases of RPLS a potentially reversible neurological condition presenting with headache, seizures, lethargy, confusion, blindness, and other visual or neurological disturbances, associated with hypertension have been reported in axitinib-treated patients. If RPLS is suspected, axitinib must be permanently discontinued.

Embryo-fetal toxicity: axitinib can cause fetal harm based on its mechanism of action. Females of reproductive potential must use effective contraception during treatment with Renaxen 5 MG and for at least 1 week after the final dose. Males with female partners of reproductive potential must use effective contraception during treatment and for at least 1 week after the last dose. Breastfeeding is not recommended during treatment and for at least 2 weeks after the final dose.

Who Should Use Renaxen 5 MG (Axitinib)?

Renaxen 5 MG (Axitinib) is indicated for adult patients across three oncology settings in advanced renal cell carcinoma: (1) second-line monotherapy at 5 mg twice daily for patients with advanced RCC after failure of one prior systemic therapy (sunitinib, bevacizumab, temsirolimus, or cytokine-based regimens); (2) first-line combination therapy at 5 mg twice daily in combination with pembrolizumab 200 mg Q3W for treatment-naïve advanced RCC; and (3) first-line combination therapy at 5 mg twice daily in combination with avelumab 10 mg/kg Q2W for treatment-naïve advanced RCC in PD-L1-positive patients.

The 5 mg film-coated tablet formulation with a 60-tablet pot is clinically appropriate for any patient requiring the axitinib 5 mg BID starting dose or dose escalation to 10 mg BID the dosing table in this content specifies the precise Renaxen 5 MG tablet counts for each dose level. Oncologists must assess baseline cardiovascular function and blood pressure status, hepatic and renal function, thyroid function (TSH), urine protein (via spot urine protein-to-creatinine ratio), haematological parameters, and all concomitant CYP3A4/5-modifying medications before prescribing any axitinib dose.

Patients with a history of arterial or venous thromboembolic events within 12 months, those with uncontrolled hypertension, and those with current or recent haemorrhage require individualised benefit-risk assessment by the treating oncologist before axitinib initiation. Patients who are pregnant, planning a pregnancy, or of reproductive potential without adequate contraception require mandatory pre-therapy counselling. Oncologists seeking comprehensive targeted agent support across kidney cancer programmes can review the full range of kidney cancer medicines at Mediaid Pharmacy, including Renaxen 5 MG Axitinib for second-line and combination first-line RCC therapy planning.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Renaxen 5 MG (Axitinib)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping capacity. Renaxen 5 MG (Axitinib) manufactured by Everest Pharmaceuticals Ltd. of Bangladesh, formulated as film-coated tablets in 60-tablet pots is stocked and available for international supply. All orders are supported by pricing quotations, stock confirmation, and end-to-end delivery tracking. Hospitals, specialist oncology and urology clinics, cancer centres, distributors, and patients in countries where axitinib is approved can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries about oral axitinib tablets for renal cell carcinoma including current stock availability, pricing, and international delivery timelines. Institutions and distributors sourcing multiple oncology medicines in a single consolidated shipment can request a combined quotation from the Mediaid Pharmacy team after browsing the full catalogue.

Why Choose Renaxen 5 MG (Axitinib) from Mediaid Pharmacy?

Renaxen 5 MG is manufactured by Everest Pharmaceuticals Ltd. of Bangladesh and delivers axitinib the selective VEGFR-1/2/3 inhibitor whose 5 mg BID dose anchored the AXIS Phase III trial (44% improvement in median PFS: 6.7 vs 4.7 months; HR 0.665; P<0.0001 versus sorafenib in second-line advanced RCC), the KEYNOTE-426 Phase III trial (47% reduction in risk of death: HR 0.53; P<0.0001; median PFS 15.1 vs 11.1 months; HR 0.69; P<0.001 versus sunitinib in first-line advanced RCC plus pembrolizumab), and the JAVELIN Renal 101 Phase III trial (median PFS 13.8 vs 7.2 months; HR 0.61; P<0.001 in PD-L1-positive first-line advanced RCC plus avelumab).

The defining procurement advantage of sourcing Renaxen 5 MG from Mediaid Pharmacy is complete reference-label starting-dose coverage from a single generic axitinib supplier: the 60-tablet pot provides a 30-day supply at the full 5 mg BID starting dose (2 tablets per day) and a 15-day supply at the 10 mg BID escalated dose (4 tablets per day) covering both the starting dose and the dose escalation pathway without supplementary sourcing at these dose levels. Mediaid Pharmacy supplies Renaxen 5 MG Axitinib for kidney cancer in its 60-tablet pot format with worldwide shipping, specialist supply support, and documentation for customs clearance as required.

Every order is initiated with a prescription-based enquiry to maintain supply aligned with the treating oncologist’s clinical plan. For oncology programmes requiring a broader panel of targeted and supportive agents, the full Mediaid Pharmacy oncology medicines catalogue is available to browse, and the team can be contacted directly for consolidated multi-medicine quotations.

Frequently Asked Questions About Renaxen 5 MG (Axitinib)

What is Renaxen 5 MG and what is its generic name?

Renaxen 5 MG is a branded generic axitinib film-coated tablet manufactured by Everest Pharmaceuticals Ltd. of Bangladesh. The generic name of Renaxen 5 MG is axitinib the same active ingredient as the originator medicine Inlyta (axitinib), originally developed by Pfizer Inc. and approved by the FDA (January 2012), EMA, and other major regulatory agencies for advanced renal cell carcinoma after failure of one prior systemic therapy. Each Renaxen 5 MG film-coated tablet contains axitinib 5 mg, with the reference-label starting dose of 5 mg BID delivered by taking 1 tablet in the morning and 1 tablet in the evening. The 60-tablet pot of Renaxen 5 MG provides a complete 30-day supply at the reference-label starting dose of 5 mg BID (2 tablets per day), making Renaxen 5 MG a clinically aligned, cost-accessible generic axitinib option for oncology programmes treating advanced RCC patients in the second-line setting and in immunotherapy-TKI combination regimens worldwide.

How should Renaxen 5 MG (Axitinib) tablets be taken?

Renaxen 5 MG (Axitinib) tablets are taken orally at the dose and schedule prescribed by the treating oncologist. The reference-label starting dose of axitinib is 5 mg twice daily (BID) 1 Renaxen 5 MG tablet in the morning and 1 Renaxen 5 MG tablet in the evening, approximately 12 hours apart, totalling 2 tablets (10 mg) per day. Axitinib can be taken with or without food; unlike some other VEGFR TKIs, there is no documented clinically significant food effect on axitinib bioavailability, though high-fat meals may modestly increase axitinib exposure. Patients should be advised to avoid grapefruit and grapefruit juice throughout treatment, as these contain potent CYP3A4 inhibitors that increase axitinib systemic exposure. Tablets should be swallowed whole with a glass of water and must not be crushed, chewed, or split. If a dose is missed and the next scheduled dose is due within a few hours, the missed dose should be skipped; patients must not double the next dose to compensate for a missed dose. Any concerns about administration should be reported to the treating oncologist immediately.

What are the most common side effects of Renaxen 5 MG (Axitinib)?

The most common side effects of axitinib across all approved indications and dose levels include diarrhoea (approximately 55%, the most frequently reported adverse event), hypertension (approximately 40%; a characteristic on-target VEGFR2 effect), fatigue (approximately 39%), decreased appetite (approximately 34%), nausea (approximately 32%), dysphonia or hoarseness (approximately 31%; a distinctive axitinib-associated adverse event), hand-foot syndrome / palmar-plantar erythrodysaesthesia (approximately 27%), weight decrease (approximately 25%), vomiting (approximately 24%), and hypothyroidism (approximately 19%; among the highest incidence of any VEGFR TKI). Dysphonia is a distinctive axitinib-associated adverse event that is clinically important for patient counselling, as it can cause significant patient distress but does not typically require dose modification. Hypertension is a dose-dependent, on-target VEGFR2 inhibition effect and has been associated with improved progression-free survival outcomes in several analyses requiring prompt management rather than automatic dose reduction where controllable. Serious adverse events including severe hypertension, arterial or venous thromboembolic events, haemorrhage, GI perforation, and reversible posterior leukoencephalopathy syndrome (RPLS) require immediate oncologist assessment and may necessitate dose interruption or permanent discontinuation. Consult your prescribing oncologist regarding your individual risk profile before and during treatment.

What is the evidence base for axitinib in advanced renal cell carcinoma (RCC)?

The pivotal evidence for axitinib in advanced RCC is derived from the Phase III AXIS trial (Axitinib versus Sorafenib in Advanced RCC), which enrolled 723 patients with advanced clear cell RCC who had progressed after one prior systemic therapy (sunitinib in 54%, cytokine-based therapy in 35%, bevacizumab in 8%, or temsirolimus in 3%). Axitinib 5 mg BID significantly extended median PFS compared to sorafenib 400 mg BID (6.7 months vs 4.7 months; HR 0.665; 95% CI 0.544–0.812; P<0.0001), with the PFS advantage consistent across all pre-specified subgroups. Objective response rate (ORR) was 19.4% with axitinib versus 9.4% with sorafenib. In first-line advanced RCC, the KEYNOTE-426 Phase III trial (861 patients) established the axitinib-plus-pembrolizumab combination as a superior alternative to sunitinib, delivering OS HR 0.53 (P<0.0001) and PFS HR 0.69 (P<0.001) across all IMDC risk groups. The JAVELIN Renal 101 Phase III trial (886 patients) confirmed the axitinib-plus-avelumab combination’s superiority to sunitinib in PD-L1-positive patients (PFS HR 0.61; P<0.001). Renaxen 5 MG delivers axitinib 5 mg BID at the exact AXIS trial, KEYNOTE-426, and JAVELIN Renal 101 reference starting dose, with 60 tablets from a single pot providing a clinically aligned 30-day supply.

Is Renaxen 5 MG (Axitinib) safe during pregnancy or while breastfeeding?

No. Axitinib including in the Renaxen 5 MG film-coated tablet formulation can cause fetal harm based on its mechanism of action and confirmed animal reproductive toxicology data, which demonstrated embryotoxicity and teratogenicity at exposures within or below the human therapeutic range. Females of reproductive potential must use effective contraception during treatment with Renaxen 5 MG and for at least 1 week after the final dose. Males with female partners of reproductive potential must use effective contraception during treatment and for at least 1 week after the last dose. Breastfeeding is not recommended during treatment and for at least 2 weeks after the final dose, as it has not been established whether axitinib or its metabolites are excreted in human breast milk. Patients who are pregnant, planning a pregnancy, or breastfeeding must discuss their individual circumstances with their treating oncologist before initiating axitinib therapy.

Can I order Renaxen 5 MG (Axitinib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Renaxen 5 MG (Axitinib) manufactured by Everest Pharmaceuticals Ltd. of Bangladesh, film-coated tablets, 60 tablets per pot to oncology centres, hospitals, distributors, and patients globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com, for pricing on Renaxen 5 MG, current stock availability, and international delivery details for your country. Oncology teams sourcing Renaxen 5 MG Axitinib alongside other targeted agents can browse the complete range of oncology medicines at Mediaid Pharmacy and request a consolidated multi-medicine quotation. All orders are supported by prescription verification, pricing documentation, and customs clearance support as required for international shipments.

Order Renaxen 5 MG (Axitinib) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128  |  Email: info@mediaidpharmacy.com

Message on WhatsApp

Reviews

There are no reviews yet.

Be the first to review “Renaxen 5 MG (Axitinib)”

Your email address will not be published. Required fields are marked *